Nutrinia
Neonatal Gastrointestinal Treatment
Company Overview
Snapshot
Founded in August 2003 by Naim Shehadeh, MD, Nutrinia operated with 1–10 employees. The company raised a total of $44.1M across 4 funding rounds from 9 investors. BioHealth Partners and TPG Biotech.
Business overview
Nutrinia is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company's core product is an oral insulin formulation designed to enhance gut adaptation and rehabilitation. This powder formulation can be mixed with saline or infant formula and is intended to target local GI issues without systemic absorption, serving the Health Tech & Life Sciences sector, specifically in pharmaceuticals for babies.
Strategic signal
Nutrinia ceased operations in May 2020, indicating a significant strategic shift and the conclusion of its development efforts in neonatal gastrointestinal treatments. This event signals to investors and innovation teams the company's exit from the market and the discontinuation of its product pipeline.
Log in to access full profile ›Company Intelligence Q&A
- What is Nutrinia's primary focus?
- Nutrinia specializes in neonatology, developing pharmaceuticals to treat rare gastrointestinal conditions in infants.
- What was the company's last disclosed funding round?
- BioHealth Partners and TPG Biotech.
- Who founded Nutrinia?
- Nutrinia was founded by Naim Shehadeh, MD, in August 2003.
- What is the status of Nutrinia?
- Nutrinia is non-active and ceased to operate in May 2020.
- What is the core technology developed by Nutrinia?
- Nutrinia developed an oral insulin formulation in powder form, designed to enhance gut development and promote bowel adaptation in infants by targeting local GI issues without systemic exposure.